City of Hope Medical Center - Recruiting 18 years to 69 years. - A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years. - Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
National Institutes of Health Clinical Center (CC) - Recruiting 6 years to 80 years. - Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years. - Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients.
National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older. - Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia.
University of British Columbia - Recruiting N/A to 18 years. - Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease.
Immunomedics, Inc. - Recruiting 18 years or older. - A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
Fred Hutchinson Cancer Research Center - Recruiting N/A or older. - A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial.
Clobetasol Oral Rinse; Chronic GVHD organ staging; Assessment of Oral GVHD; Numeric rating scales for oral pain; Oral Global Scale; Painometer (POM) Assessment; Oral Health Impact Profile-OHIP-14; Biopsy of buccal mucosa; Short ACTH stimulation test
Fred Hutchinson Cancer Research Center - Recruiting 2 years or older. - A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation.
National Cancer Institute (NCI) - Recruiting 16 years to 65 years. - A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation
A.O. Ospedale Papa Giovanni XXIII - Recruiting 18 years to 70 years. - UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC) FOR THE TREATMENT OF SEVERE (GRADE III-IV) STEROID-RESISTANT GRAFT VERSUS HOST DISEASE (GvHD): A PHASE I/II TRIAL.
Soligenix - Recruiting 18 years or older. - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBecr (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD.
National Institutes of Health Clinical Center (CC) - Recruiting 10 years to 80 years. - Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans.
Xenikos - Recruiting 18 years or older. - A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins (T-Guard) for the Treatment of Steroid-resistant Acute Graft-versus-Host Disease..
Peking University People's Hospital - Recruiting 14 years to 60 years. - Infusion of Recombinant Human Granulocyte Colony Stimulating Factor Mobilized Peripheral Harvest for Poor Engraftment After Hematopoietic Stem Cell Transplantation.
University of Kansas - Recruiting 18 years or older. - A Study of Extracorporeal Photopheresis With UVADEXr in the Setting of a Standard Myeloablative Conditioning Regimen in Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for the Prevention of Graft Versus Host Disease.
H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years to 70 years. - Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.
Duke University - Recruiting 18 years or older. - Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects.
Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)
Fred Hutchinson Cancer Research Center - Recruiting N/A to 21 years. - A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children.
Neovii Biotech - Recruiting 18 years to 65 years. - Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors.
Spectrum Health Hospitals - Recruiting 18 years or older. - A Phase I Trial of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).
Washington University School of Medicine - Recruiting 18 years to 65 years. - A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation.
Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older. - A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors.
University Hospital of Liege - Recruiting N/A or older. - Infusion of Mesenchymal Stem Cells as Treatment for Steroid-Resistant Grade II to IV Acute GVHD or Poor Graft Function: a Multicenter Phase II Study.
Azienda Ospedaliera San Gerardo di Monza - Recruiting N/A or older. - Mesenchymal Stromal Cells (MSC) for the Treatment of Severe (Grade II-IV) Steroid-resistant Graft Versus Host Disease (GVHD): a Phase I Trial.
Hospital Israelita Albert Einstein - Recruiting 18 years to 60 years. - Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis.
ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate
Yale University - Recruiting 14 years to 55 years. - A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD.
Hadassah Medical Organization - Recruiting N/A to 70 years. - Enhancement of Hematopoietic Stem Cell Engraftment by Multi Donor Stem Cell Transplantation (MDT) From 2 Mismatched Donors, a Phase I-II Open Study.
Universittsklinikum Hamburg-Eppendorf - Recruiting 18 years to 65 years. - Prophylaxis of Chronic Graft-Versus-Host Disease (cGvHD) With or Without Anti-T-Lymphocyte-Globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-Identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-Study.